China probe hangover, functional foods failure depress Usana's earnings
By Hank Schultz
Last updated on
An internal investigation into business practices in China has taken some of the air out of the balloon of Usana Health Sciences, as the company’s stock price declined after an earnings report that was lower than analysts’ estimates. And a launch of a new functional foods line seems to have missed the mark.
In the midst of an internal review of its Chinese operations, Usana Health Sciences reported a 6.2% increase in sales derived almost entirely from the Asia Pacific region.
Usana Health Sciences’ shares declined as the company reported disappointing earnings and announced an internal investigation of its business in mainland China.
USANA Health Sciences reported $232.6 million in net sales in its fourth quarter, a 2.1% year-over-year increase. That amounted to $1.83 in earnings per share, but these figures disappointed analysts, and the company’s share price tumbled as a result.